ImmunityBio reports 92% revenue growth, FDA label expansion
ImmunityBio (IBRX) reported Q3 2026 net product revenue of $48.7M, up 53% YoY, and 9-month revenue of $143.6M, up 92% YoY. The FDA expanded ANKTIVA's label for BCG-unresponsive bladder cancer. R&D and SG&A expenses rose, with a net loss of $184.6M for Q3. The company has $334.3M in cash and approvals in 35 countries.
How this was made
The 30-second read
Why it matters
Regulatory win and revenue surge provide a strong catalyst for the stock.
Market read
First disclosure of FDA approval and significant revenue growth likely moves IBRX.
What to watch
Potential reimbursement challenges in new markets could limit upside.
Background
ImmunityBio announced FDA label expansion for ANKTIVA and reported Q3 revenue growth.
Ticker impact
FDA approved supplemental BLA expanding ANKTIVA indication and reported 92% Q3 revenue growth.
upward pressure as market prices in expanded label and revenue boost
First report of FDA label expansion and 92% YoY revenue increase provides fresh, material catalyst.
Market effects
Boosts biotech sector sentiment on FDA approvals.
Positive for US biotech stocks.
May influence global investors tracking immunotherapy pipelines.
Counterpoint
If the trial data later disappoints, the approval could be short-lived.
Key entities
- CompanyImmunityBio Inc.
Biotech firm developing ANKTIVA immunotherapy.
- RegulatorFDA
U.S. Food and Drug Administration granting label expansion.
